Clinical Trial Update: Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 1/2 clinical trial comparing intravesical Bacillus Calmette-Guérin (BCG) to Gemcitabine in patients with high-ri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: University Of Perugia | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: COMPLETED